Therefore, whether expression of NCR2 on NK cells from breast cancer patients would impact NK cell activation negatively or positively depends on the expression of inhibiting (PCNA) versus activating (NKp44L) cellular ligands on breast cancer cells. This evidence concerns the gene NCR2 and breast carcinoma.